Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (4580)	10/19/2000 11:55:30 AM
From: jayhawk969	Read Replies (1) \| Respond to of 10280

Thanks, I expected something like this. Eight times a normal dosage causes problems! Based on a review of the available clinical data, (R)-fluoxetine, at the highest dose tested, demonstrated a small but statistically significant increase in QTc prolongation. While we believe that this is a clinically insignificant effect, development of a lower dose would delay the New Drug Application submission by at least two years. Something still doesn't smell right. IF they were to "develop a lower dose" the effect would not go away at the 8 times current dosage level, Is there something significant in FDA testing about "8x dosage" as an upper limit. Obviously they have tested dosages at a variety of levels. What am I missing? I believe that there is something we do not know about the efficacy of new developmental drug (by Lilly) or the cost/profit ration of introducing Prozac II.